Viimeisin päivitys :
19/11/2024
Pahoinvontilääkkeet   Granisetron hydrochloride  
Injektioneste
Oraaliliuos
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axigran Saksa, Saudi-Arabia
Cadigran Intia
Cetrexon Kolumbia
Em Ex Egypti
Emegran Intia
Emetril Turkki
Grandem Intia
Granic Iran
Granicip Intia
Graniset Intia
Granisetrom Portugali
Granisetron Belgia, Chile, Ecuador, Egypti, Espanja, Iso-Britannia, Kanada, Marokko, Meksiko, Romania, Ruotsi, Saudi-Arabia, Yhdysvallat
Granitero Portugali
Granitron Itävalta
Granon Intia
Granytril Intia
Gratil Iran
Gratryl Turkki
Helminar Marokko
Kevatril Saksa
Kytril Australia, Belgia, Brasilia, Chile, Ecuador, Egypti, Espanja, Hollanti, Iran, Irlanti, Iso-Britannia, Italia, Itävalta, Japani, Kolumbia, Kreikka, Luxemburg, Malesia, Marokko, Marokko, Meksiko, Portugali, Puola, Ruotsi, Saksa, Saudi-Arabia, Suomi, Sveitsi, Tanska, Tunisia, Turkki, Unkari, Venezuela, Yhdistyneet arabiemiirikunnat
Manotrox Meksiko
Neoset Turkki
Ribosetron Saksa
Rubrum Venezuela
Suliftop Marokko
Synarex Turkki
Tentratec Meksiko
Tigron Turkki
Travigan Meksiko
Trilemes Meksiko
Vitasetron Turkki
Viitteet   Injektioneste   Viitteet : Granisetron hydrochloride  
tyyppi julkaisu
6 Lehti Trissel LA, Xu QA, Martinez JF, Fox JL.
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Am J Hosp Pharm 1994 ; 51: 2138-2142.
27 Lehti Chin A, Moon YSK, Chung KC, Gill MA.
Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days.
Am J Health-Syst Pharm 1996 ; 53: 1174-1176.
29 Lehti Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C.
Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions.
J Pharm Sci 1995 ; 84: 267-268.
48 Lehti Quercia RA, Zhang J, Fau C, Chow MSS.
Stability of granisetron hydrochloride in polypropylene syringes.
Am J Health-Syst Pharm 1996 ; 53: 2744-2746.
49 Lehti Trissel LA, Martinez JF.
Compatibility of granisetron hydrochloride with selected alkaline drugs.
Am J Health-Syst Pharm 1995 ; 52: 208.
51 Lehti Chung KC, Chin A, Gill MA.
Stability of granisetron hydrochloride in a disposable elastomeric infusion device.
Am J Health-Syst Pharm 1995 ; 52: 1541-1543.
57 Lehti Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
182 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
249 Lehti Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Lehti Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
921 Lehti Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Lehti Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410 Lehti Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Lehti Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Lehti Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Lehti Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Lehti Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1633 Lehti Walker SE, Law S.
Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions.
Can J Hosp Pharm 2002 ; 55: 27-38.
1662 Lehti Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1676 Lehti Hourcade F, Sautou-Miranda V, Normand B, Laugier M, Picq F, Chopineau J.
Compatibility of granisetron towards glass and plastics and its stability under various storage conditions.
Int J Pharm 1997 ; 154: 95-102.
1712 Lehti Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1721 Lehti Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Lehti Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Lehti Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Lehti Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Lehti Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2262 Lehti Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Lehti Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335 Lehti Canann D, Tyler L.S, Barker B, Condie C.
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3249 Lehti Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3459 Lehti Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3571 Lehti Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3805 Lehti Chen F.C, Xiong H, Liu H.M, Fang B.X, Li P.
Compatibility of butorphanol with granisetron in 0.9% sodium chloride injection packaged in glass bottles or polyolefin bags.
Am J Health-Syst Pharm 2015 ; 72:1374-1378.
3824 Lehti Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3964 Lehti Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4061 Lehti Wu George, Powers Dan, Yeung S, Chen F, Neelon K.
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous granisetron hydrochloride.
Int J Pharm Compound 2018 ; 22,1 :86-94
4116 Lehti Chen F, Zhu J, Li B, Yuan F, Wang K.
Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems.
Drug Design Dev Ther 2016 ;10:1869-1875
4310 Lehti Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
4319 Lehti Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4429 Lehti Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H.
Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration.
Medicine 2016 ; 95:25(e3824)
4603 Lehti Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 Lehti Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales